How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Background: Type 2 diabetes mellitus (T2DM) is frequently associated with the development of cardiovascular disease and chronic kidney disease (CKD). Some newer glucose-lowering agents confer both cardiac and kidney benefits, as supported by robust data from recent high-quality randomized controlled...
Gespeichert in:
| Veröffentlicht in: | Kidney & blood pressure research 2020-12, Vol.45 (6), p.823-836 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 836 |
|---|---|
| container_issue | 6 |
| container_start_page | 823 |
| container_title | Kidney & blood pressure research |
| container_volume | 45 |
| creator | Sukkar, Louisa Young, Tamara Jardine, Meg J. |
| description | Background: Type 2 diabetes mellitus (T2DM) is frequently associated with the development of cardiovascular disease and chronic kidney disease (CKD). Some newer glucose-lowering agents confer both cardiac and kidney benefits, as supported by robust data from recent high-quality randomized controlled trials. The decision-making process when selecting glucose-lowering medications for T2DM now extends beyond glycaemia and metabolic effects, and towards additional benefits such as prevention of other complications. Summary: We review the evidence for efficacy in 3 new classes of medication for T2DM and additionally discuss relevant safety issues when considering optimal agents. Key Messages: Clinicians have multiple efficacy and safety factors to consider when selecting agents for glucose lowering in T2DM, and this should help direct individualized selection of pharmacotherapy for patients. New medications offer an opportunity to prevent cardiac and renal complications in people with T2DM. |
| doi_str_mv | 10.1159/000511214 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000511214</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A645281268</galeid><doaj_id>oai_doaj_org_article_3668b3133c144a32af5b40863f841954</doaj_id><sourcerecordid>A645281268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-f9cef3f15a6b06c8e5d550d673cb1815aca43a856e0281dc4c68beca292bb1143</originalsourceid><addsrcrecordid>eNptkc1v1DAQxSMEomXhwB0hS73AIcXfm5yq7RbaFQtIq_YcOc44OCTxYidU5a_Huyk5IE4ejX_vjZ8nSV4TfE6IyD9gjAUhlPAnySnhlKWYcPb0WOOU41yeJC9CaA4YxvR5csIYXRLBxWnS3Lh7dOXQ8B3QDjT0A_qiGufRTvWV6-xvqNDa9YN3bRvLW29VG9CmN8536BLCgO4CIGeOBl_dL2jRdTtqFyDdunvwtq_Rqo624eJl8sxEMbx6PBfJ3aePt-ubdPvterNebVPNczykJtdgmCFCyRJLnYGohMCVXDJdkiy2teJMZUICphmpNNcyK0ErmtOyJDH4ItlMvpVTTbH3tlP-oXDKFseG83Wh_GB1CwWTUcsIY5pwrhhVRpQcZ5KZjJNcHLzeTV57736OMW7R2aChbVUPbgwF5XIpiZTLPKJn_6CNG30fk0YqY0xQGSctkvOJqlWcb-M_Dj4m0qqCzmrXg7Gxv5JcxHBUZlHwfhJo70LwYOZEBBeH7Rfz9iP79vEJY9lBNZN_1x2BNxPwQ_ka_AzM-rP_Xn--3E1Esa8M-wPB97sJ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2483352631</pqid></control><display><type>article</type><title>How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Karger Open Access</source><creator>Sukkar, Louisa ; Young, Tamara ; Jardine, Meg J.</creator><creatorcontrib>Sukkar, Louisa ; Young, Tamara ; Jardine, Meg J.</creatorcontrib><description>Background: Type 2 diabetes mellitus (T2DM) is frequently associated with the development of cardiovascular disease and chronic kidney disease (CKD). Some newer glucose-lowering agents confer both cardiac and kidney benefits, as supported by robust data from recent high-quality randomized controlled trials. The decision-making process when selecting glucose-lowering medications for T2DM now extends beyond glycaemia and metabolic effects, and towards additional benefits such as prevention of other complications. Summary: We review the evidence for efficacy in 3 new classes of medication for T2DM and additionally discuss relevant safety issues when considering optimal agents. Key Messages: Clinicians have multiple efficacy and safety factors to consider when selecting agents for glucose lowering in T2DM, and this should help direct individualized selection of pharmacotherapy for patients. New medications offer an opportunity to prevent cardiac and renal complications in people with T2DM.</description><identifier>ISSN: 1420-4096</identifier><identifier>EISSN: 1423-0143</identifier><identifier>DOI: 10.1159/000511214</identifier><identifier>PMID: 33271545</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Blood glucose ; cardiovascular disease ; Cardiovascular diseases ; Chronic kidney failure ; Clinical trials ; Complications ; Complications and side effects ; Decision making ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Drug dosages ; Drug therapy ; Glucagon ; glucagon-like peptide-1 receptor agonists ; Glucose ; Heart attacks ; Heart failure ; Hospitalization ; Hypoglycemic agents ; Kidney diseases ; Kidneys ; Mortality ; Peptides ; Prevention ; Reagents ; Review Article ; Risk factors ; Safety factors ; sodium-glucose co-transporter 2 inhibitors ; Testing ; Type 2 diabetes</subject><ispartof>Kidney & blood pressure research, 2020-12, Vol.45 (6), p.823-836</ispartof><rights>2020 The Author(s). Published by S. Karger AG, Basel</rights><rights>2020 The Author(s). Published by S. Karger AG, Basel.</rights><rights>COPYRIGHT 2020 S. Karger AG</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c490t-f9cef3f15a6b06c8e5d550d673cb1815aca43a856e0281dc4c68beca292bb1143</cites><orcidid>0000-0001-7409-2938</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,2096,27612,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33271545$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sukkar, Louisa</creatorcontrib><creatorcontrib>Young, Tamara</creatorcontrib><creatorcontrib>Jardine, Meg J.</creatorcontrib><title>How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?</title><title>Kidney & blood pressure research</title><addtitle>Kidney Blood Press Res</addtitle><description>Background: Type 2 diabetes mellitus (T2DM) is frequently associated with the development of cardiovascular disease and chronic kidney disease (CKD). Some newer glucose-lowering agents confer both cardiac and kidney benefits, as supported by robust data from recent high-quality randomized controlled trials. The decision-making process when selecting glucose-lowering medications for T2DM now extends beyond glycaemia and metabolic effects, and towards additional benefits such as prevention of other complications. Summary: We review the evidence for efficacy in 3 new classes of medication for T2DM and additionally discuss relevant safety issues when considering optimal agents. Key Messages: Clinicians have multiple efficacy and safety factors to consider when selecting agents for glucose lowering in T2DM, and this should help direct individualized selection of pharmacotherapy for patients. New medications offer an opportunity to prevent cardiac and renal complications in people with T2DM.</description><subject>Blood glucose</subject><subject>cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Chronic kidney failure</subject><subject>Clinical trials</subject><subject>Complications</subject><subject>Complications and side effects</subject><subject>Decision making</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Glucagon</subject><subject>glucagon-like peptide-1 receptor agonists</subject><subject>Glucose</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Hospitalization</subject><subject>Hypoglycemic agents</subject><subject>Kidney diseases</subject><subject>Kidneys</subject><subject>Mortality</subject><subject>Peptides</subject><subject>Prevention</subject><subject>Reagents</subject><subject>Review Article</subject><subject>Risk factors</subject><subject>Safety factors</subject><subject>sodium-glucose co-transporter 2 inhibitors</subject><subject>Testing</subject><subject>Type 2 diabetes</subject><issn>1420-4096</issn><issn>1423-0143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkc1v1DAQxSMEomXhwB0hS73AIcXfm5yq7RbaFQtIq_YcOc44OCTxYidU5a_Huyk5IE4ejX_vjZ8nSV4TfE6IyD9gjAUhlPAnySnhlKWYcPb0WOOU41yeJC9CaA4YxvR5csIYXRLBxWnS3Lh7dOXQ8B3QDjT0A_qiGufRTvWV6-xvqNDa9YN3bRvLW29VG9CmN8536BLCgO4CIGeOBl_dL2jRdTtqFyDdunvwtq_Rqo624eJl8sxEMbx6PBfJ3aePt-ubdPvterNebVPNczykJtdgmCFCyRJLnYGohMCVXDJdkiy2teJMZUICphmpNNcyK0ErmtOyJDH4ItlMvpVTTbH3tlP-oXDKFseG83Wh_GB1CwWTUcsIY5pwrhhVRpQcZ5KZjJNcHLzeTV57736OMW7R2aChbVUPbgwF5XIpiZTLPKJn_6CNG30fk0YqY0xQGSctkvOJqlWcb-M_Dj4m0qqCzmrXg7Gxv5JcxHBUZlHwfhJo70LwYOZEBBeH7Rfz9iP79vEJY9lBNZN_1x2BNxPwQ_ka_AzM-rP_Xn--3E1Esa8M-wPB97sJ</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Sukkar, Louisa</creator><creator>Young, Tamara</creator><creator>Jardine, Meg J.</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7409-2938</orcidid></search><sort><creationdate>20201201</creationdate><title>How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?</title><author>Sukkar, Louisa ; Young, Tamara ; Jardine, Meg J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-f9cef3f15a6b06c8e5d550d673cb1815aca43a856e0281dc4c68beca292bb1143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Blood glucose</topic><topic>cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Chronic kidney failure</topic><topic>Clinical trials</topic><topic>Complications</topic><topic>Complications and side effects</topic><topic>Decision making</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Glucagon</topic><topic>glucagon-like peptide-1 receptor agonists</topic><topic>Glucose</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Hospitalization</topic><topic>Hypoglycemic agents</topic><topic>Kidney diseases</topic><topic>Kidneys</topic><topic>Mortality</topic><topic>Peptides</topic><topic>Prevention</topic><topic>Reagents</topic><topic>Review Article</topic><topic>Risk factors</topic><topic>Safety factors</topic><topic>sodium-glucose co-transporter 2 inhibitors</topic><topic>Testing</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sukkar, Louisa</creatorcontrib><creatorcontrib>Young, Tamara</creatorcontrib><creatorcontrib>Jardine, Meg J.</creatorcontrib><collection>Karger Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Kidney & blood pressure research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sukkar, Louisa</au><au>Young, Tamara</au><au>Jardine, Meg J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?</atitle><jtitle>Kidney & blood pressure research</jtitle><addtitle>Kidney Blood Press Res</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>45</volume><issue>6</issue><spage>823</spage><epage>836</epage><pages>823-836</pages><issn>1420-4096</issn><eissn>1423-0143</eissn><abstract>Background: Type 2 diabetes mellitus (T2DM) is frequently associated with the development of cardiovascular disease and chronic kidney disease (CKD). Some newer glucose-lowering agents confer both cardiac and kidney benefits, as supported by robust data from recent high-quality randomized controlled trials. The decision-making process when selecting glucose-lowering medications for T2DM now extends beyond glycaemia and metabolic effects, and towards additional benefits such as prevention of other complications. Summary: We review the evidence for efficacy in 3 new classes of medication for T2DM and additionally discuss relevant safety issues when considering optimal agents. Key Messages: Clinicians have multiple efficacy and safety factors to consider when selecting agents for glucose lowering in T2DM, and this should help direct individualized selection of pharmacotherapy for patients. New medications offer an opportunity to prevent cardiac and renal complications in people with T2DM.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>33271545</pmid><doi>10.1159/000511214</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-7409-2938</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1420-4096 |
| ispartof | Kidney & blood pressure research, 2020-12, Vol.45 (6), p.823-836 |
| issn | 1420-4096 1423-0143 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000511214 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; Karger Open Access |
| subjects | Blood glucose cardiovascular disease Cardiovascular diseases Chronic kidney failure Clinical trials Complications Complications and side effects Decision making Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Drug dosages Drug therapy Glucagon glucagon-like peptide-1 receptor agonists Glucose Heart attacks Heart failure Hospitalization Hypoglycemic agents Kidney diseases Kidneys Mortality Peptides Prevention Reagents Review Article Risk factors Safety factors sodium-glucose co-transporter 2 inhibitors Testing Type 2 diabetes |
| title | How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T21%3A58%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20Do%20the%20Recent%20Major%20Randomized%20Controlled%20Trials%20Inform%20Best%20Use%20of%20the%20Novel%20Glucose-Lowering%20Agents?&rft.jtitle=Kidney%20&%20blood%20pressure%20research&rft.au=Sukkar,%20Louisa&rft.date=2020-12-01&rft.volume=45&rft.issue=6&rft.spage=823&rft.epage=836&rft.pages=823-836&rft.issn=1420-4096&rft.eissn=1423-0143&rft_id=info:doi/10.1159/000511214&rft_dat=%3Cgale_cross%3EA645281268%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2483352631&rft_id=info:pmid/33271545&rft_galeid=A645281268&rft_doaj_id=oai_doaj_org_article_3668b3133c144a32af5b40863f841954&rfr_iscdi=true |